Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-26-016708
Filing Date
2026-04-24
Accepted
2026-04-24 16:15:45
Documents
18
Period of Report
2026-06-04

Document Format Files

Seq Description Document Type Size
1 DEF 14A nktr-20260604.htm   iXBRL DEF 14A 1542630
3 GRAPHIC logo_nektar.jpg GRAPHIC 14135
4 GRAPHIC ny20063621x1-pc_1.jpg GRAPHIC 541919
5 GRAPHIC ny20063621x1-pc_2.jpg GRAPHIC 543863
6 GRAPHIC ny20063621x1_barchart01.jpg GRAPHIC 161037
7 GRAPHIC ny20063621x1_pvp01x1.jpg GRAPHIC 188933
8 GRAPHIC ny20063621x1_pvp02x1.jpg GRAPHIC 158248
  Complete submission text file 0001140361-26-016708.txt   6711425

Data Files

Seq Description Document Type Size
2 INLINE XBRL TAXONOMY EXTENSION - SCHEMA nktr-20260604.xsd EX-101.SCH 2158
21 EXTRACTED XBRL INSTANCE DOCUMENT nktr-20260604_htm.xml XML 321453
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-24006 | Film No.: 26894220
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)